ETFs with BMY as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|7.56%||iShares U.S. Pharmaceutical ETF (IHE)||+11.96 (11.41%)|
|6.14%||PowerShares Dynamic Pharmaceuticals (PJP)||+7.11 (15.80%)|
|5.61%||Merrill Lynch Pharmaceutical HOLDRS (PPH)||+4.61 (9.77%)|
|4.35%||SPDR S&P Pharmaceuticals ETF (XPH)||+13.19 (17.70%)|
|4.25%||Select Sector SPDR Fund - Health Care (XLV)||+4.92 (9.86%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
Bristol-Myers Squibb Company (which may be referred to as Bristol-Myers Squibb, BMS, the Company, we, our or us) was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. We are engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Over the last few years, we executed our strategy to transform into a next generation biopharmaceutical company. This transformation encompassed all areas of our business and operations. As part of this strategy, we have divested our non-pharmaceutical businesses, implemented our acquisition and licensing strategy known as the “string-of-pearls”, and executed our productivity transformation initiative (PTI). ... More ...